摘要
目的对体外循环下心脏瓣膜置换手术患者输注右美托咪定,分析该药品对患者起到的脑保护作用。方法在2014年1月-2018年6月开展研究,研究样本均来自于我院实施体外循环下心脏瓣膜置换手术的52例患者,根据随机数字表法将样本平均分为生理盐水注射的盐水组(26例)与右美托咪定注射的右美组(26例),两组使用方法相同且均在麻醉诱导前15min完成,记录并对比两组患者不同时间点内血浆S-100β蛋白、神经元特异性烯醇化酶(NES)。结果在T2、T3、T4阶段,右美组血浆S-100β蛋白[(3.68±1.02)μg/L、(4.02±1.04)μg/L、(6.03±1.07)μg/L]低于盐水组,NES[(16.73±2.98)μg/L、(19.41±3.79)μg/L、(23.44±3.80)μg/L]低于盐水组,差异显著(P<0.05)。结论对体外循环下心脏瓣膜置换手术患者输注右美托咪定,可改善患者的脑缺氧情况,起到显著的脑保护作用,应用价值显著。
Objective To inject dexmedetomidine in patients undergoing heart valve replacement under cardiopulmonary bypass to analyze the protective effect of the drug on patients. Methods The study was conducted from January 2014 to June 2018. The study samples were 52 patients who underwent cardiopulmonary bypass in our hospital. According to the random number table method, the samples were divided into saline group(26 cases) and dexmedetomidine group(26 cases). Both groups used the same method and were completed 15 minutes before induction of anesthesia. The plasma S-100β protein and neuron-specific enolase(NES) were recorded and compared between the two groups at different time points. Results At the T2, T3, and T4 stages, the plasma S-100β protein [(3.68±1.02) μg/L,(4.02±1.04) μg/L, and(6.03±1.07) μg/L] of dexmedetomidine group were lower than those of saline group, NES [(16.73±2.98) μg/L,(19.41±3.79) μg/L,(23.44±3.80) μg/L] were lower than those of saline group, and P<0.05. Conclusion Infusion of dexmedetomidine in patients undergoing cardiac valve replacement under cardiopulmonary bypass can improve cerebral hypoxia, play a significant role in brain protection, and has significant application value.
作者
李小静
吉晓丽
蔡鹏举
袁志国
孙灿林
Xiaojing LI;Xiaoli JI;Pengju CAI;Zhiguo YUAN;Canlin SUN(Department of Anesthesiology,Taizhou People's Hospital,Taizhou 225300,China)
出处
《心血管外科杂志（电子版）》
2018年第4期615-616,共2页
Journal of Cardiovascular Surgery(Electronic Edition)
关键词
体外循环
心脏瓣膜置换手术
右美托咪定
脑保护
Extracorporeal circulation
Heart valve replacement surgery
Dexmedetomidine
Brain protection
